Kenvue Inc. (NYSE:KVUE) Shares Acquired by Intact Investment Management Inc.

Intact Investment Management Inc. increased its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 7.6% in the second quarter, Holdings Channel reports. The firm owned 162,303 shares of the company’s stock after buying an additional 11,417 shares during the quarter. Intact Investment Management Inc.’s holdings in Kenvue were worth $2,951,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Manchester Capital Management LLC increased its holdings in shares of Kenvue by 80.8% in the first quarter. Manchester Capital Management LLC now owns 1,186 shares of the company’s stock valued at $25,000 after purchasing an additional 530 shares during the period. Pacific Capital Wealth Advisors Inc. purchased a new stake in shares of Kenvue in the fourth quarter valued at approximately $28,000. Mather Group LLC. acquired a new position in shares of Kenvue during the 1st quarter worth $28,000. Riverview Trust Co acquired a new position in Kenvue during the first quarter worth about $33,000. Finally, MV Capital Management Inc. grew its holdings in shares of Kenvue by 71.2% in the 1st quarter. MV Capital Management Inc. now owns 1,544 shares of the company’s stock worth $33,000 after acquiring an additional 642 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

Kenvue Trading Up 0.9 %

NYSE KVUE traded up $0.20 during mid-day trading on Friday, reaching $21.95. 14,008,532 shares of the stock were exchanged, compared to its average volume of 18,622,010. The business’s fifty day simple moving average is $19.54 and its 200 day simple moving average is $19.56. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.99. The stock has a market capitalization of $42.03 billion, a PE ratio of 28.13, a PEG ratio of 2.07 and a beta of 1.38. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $23.33.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.28 by $0.04. The company had revenue of $4 billion during the quarter, compared to the consensus estimate of $3.93 billion. Kenvue had a net margin of 9.63% and a return on equity of 21.06%. The company’s quarterly revenue was down .3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.32 EPS. On average, research analysts anticipate that Kenvue Inc. will post 1.13 earnings per share for the current fiscal year.

Kenvue Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, August 28th. Shareholders of record on Wednesday, August 14th were given a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a yield of 3.74%. The ex-dividend date was Wednesday, August 14th. This is an increase from Kenvue’s previous quarterly dividend of $0.20. Kenvue’s payout ratio is 105.13%.

Wall Street Analyst Weigh In

KVUE has been the subject of several research reports. Citigroup reduced their price objective on Kenvue from $21.00 to $20.00 and set a “neutral” rating for the company in a report on Wednesday, July 10th. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Kenvue from $23.00 to $24.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. HSBC raised their target price on shares of Kenvue from $20.00 to $21.00 and gave the company a “hold” rating in a report on Wednesday, May 8th. JPMorgan Chase & Co. upped their price target on shares of Kenvue from $22.00 to $24.00 and gave the company an “overweight” rating in a report on Wednesday, August 7th. Finally, UBS Group increased their price target on shares of Kenvue from $20.00 to $22.00 and gave the company a “neutral” rating in a research report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $22.64.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.